Zerodha (Trading & Demat Account)
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
Zerodha (Trading & Demat Account)
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
|
Track all the latest updates and news of Saamya Biotech IPO.
July 1, 2024 2:30:00 PM
Biopharma deal activity plummeted down to Earth in the second quarter, with just a handful of M&A transactions and IPOs studding the mostly dark skies. | The slow quarter follows an exciting first one ...
Published by : FierceBiotechJune 28, 2024 8:32:00 AM
In the latest sign that biotech�s return to the public markets remains somewhat lackluster, Alumis has downsized its IPO as the company prepares to list on the Nasdaq this morning. The biotech started ...
Published by : FierceBiotechJune 28, 2024 6:32:00 PM
In all, the IPO and private placement are expected to gross $250 million, Alumis said. Alumis also granted to the IPO's underwriters a 30-day option to buy up to an additional 1,968,750 shares at the ...
Published by : The Business JournalsJune 28, 2024 7:05:00 PM
Alumis is debuting in an initial public offering Friday on the Nasdaq, though the $250 million IPO is less than its initial targeted raise of $274 million just days ago.
Published by : BioSpaceMay 5, 2023 3:30:00 AM
The company raised $540 million from the sale of 30 million shares at $18 apiece, in the largest biotech IPO in the US since Sana Biotech went public in early 2021 with a $588 million raise that ...
Published by : pharmaphorumJune 28, 2024 1:45:00 PM
Alumis, an immunology drug developer on the cusp of Phase 3, will go public Friday in a smaller IPO than it originally projected. The Bay Area startup sold 13.12 million shares $ALMS at $16 apiece to ...
Published by : ENDPOINTS NEWSApril 23, 2024 8:06:00 PM
Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good morning! After a two-year dry spell, initial public offerings by biotech companies showed ...
Published by : MSNJune 24, 2024 3:30:00 AM
It would be the first Bay Area biotech IPO since February, when Kyverna Therapeutics Inc.'s $336.2 million net offering capped a micro-flurry of offerings. That wave included Metagenomi Inc. of ...
Published by : The Business JournalsJune 28, 2024 1:44:00 PM
The offering is expected to close on 1 July. Earlier this month, the US-based biotech said that it planned to use part of the IPO proceeds to advance its lead asset ESK-001 into multiple Phase III ...
Published by : Yahoo FinanceOctober 12, 2023 9:50:00 PM
After a decade of significant challenges, biotech's long-term sustainability depends on making fundamental changes to its traditional business model. A commonly held perception in the biotech ...
Published by : NatureMay 19, 2020 3:30:00 AM
Legend Biotech is spinning out from parent firm GenScript Biotech to pursue treatments in CAR T cell therapies for multiple myeloma. Legend Biotech is spinning out from parent firm GenScript ...
Published by : TheStreet.comAugust 11, 2023 3:31:00 AM
Concord Biotech is expected to announce its share allotment status today, August 11. The shares of Concord Biotech were subscribed almost 25 times. The shares are expected to be listed on the ...
Published by : Business Insider IndiaIPO Allotment Status is now available online for Saamya Biotech India Limited.
Saamya Biotech India Limited IPO was closed on September 28, 2007.
Saamya Biotech India Limited IPO listing info:
IPO Listing Date: Friday, October 19, 2007
BSE Script Code: 532905
Listing in: B1 Group
ISIN: INE320H01019
Issue Price: Rs 10/- Per Equity Share
Face Value : Rs 10/- Per Equity Share
Incorporated in 2002, Saamya Biotech India Limited (SBIL) is a Hyderabad based Biotech company. SBIL manufacture and market bio pharmaceutical and recombinant protein products to medical and other industries.
SBIL is entering the capital markets with an initial public offering, IPO of 1,50,00,000 Equity Shares through a Fixed Price Issue.
The price for the issue has been fixed at Rs 10/- for equity share of Rs 10/-. The issue opens on September 25, 2007, and closes for subscription on September 28, 2007. The equity shares of the company are proposed to be listed on the Bombay Stock Exchange (BSE).
The Saamya Biotech IPO is proposed to open on September 25, 2007. The IPO application ends on September 28, 2007.
Retail investors can apply in the retail or non-institutional investor category from September 25, 2007 to September 28, 2007. The Saamya Biotech IPO can be applied online through Net Bank (ASBA method) or the stock broker (UPI method).
The Saamya Biotech IPO will open for subscription on September 25, 2007. The public issue will close on September 28, 2007.
Useful Articles
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|
|
DRHP
